<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36905145</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study.</ArticleTitle><Pagination><StartPage>194</StartPage><EndPage>202</EndPage><MedlinePgn>194-202</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciad143</ELocationID><Abstract><AbstractText Label="BACKGROUND">Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC.</AbstractText><AbstractText Label="METHODS">We performed a cross-sectional analysis (May/June 2022) within a prospective multicenter healthcare worker (HCW) cohort in north-eastern Switzerland. HCWs were stratified by viral variant and vaccination status at time of their first positive SARS-CoV-2 nasopharyngeal swab. HCWs without positive swab and with negative serology served as controls. The sum of 18 self-reported PASC symptoms was modeled with univariable and multivariable negative-binomial regression to analyze the association of mean symptom number with viral variant and vaccination status.</AbstractText><AbstractText Label="RESULTS">Among 2912 participants (median age: 44 years; 81.3% female), PASC symptoms were significantly more frequent after wild-type infection (estimated mean symptom number: 1.12; P &lt; .001; median time since infection: 18.3 months), after Alpha/Delta infection (0.67 symptoms; P &lt; .001; 6.5 months), and after Omicron BA.1 infections (0.52 symptoms; P = .005; 3.1 months) versus uninfected controls (0.39 symptoms). After Omicron BA.1 infection, the estimated mean symptom number was 0.36 for unvaccinated individuals versus 0.71 with 1-2 vaccinations (P = .028) and 0.49 with &#x2265;3 prior vaccinations (P = .30). Adjusting for confounders, only wild-type (adjusted rate ratio [aRR]: 2.81; 95% confidence interval [CI]: 2.08-3.83) and Alpha/Delta infections (aRR: 1.93; 95% CI: 1.10-3.46) were significantly associated with the outcome.</AbstractText><AbstractText Label="CONCLUSIONS">Previous infection with pre-Omicron variants was the strongest risk factor for PASC symptoms among our HCWs. Vaccination before Omicron BA.1 infection was not associated with a clear protective effect against PASC symptoms in this population.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kahlert</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strahm</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;sewell</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cusini</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Cantonal Hospital of Grisons, Chur, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brucher</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ambulatory Services, Psychiatry Services of the Canton of St. Gallen (South), St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goppel</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ambulatory Services, Psychiatry Services of the Canton of St. Gallen (North), St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf6;ller</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Clienia Littenheid, Littenheid, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf6;ller</LastName><ForeName>J Carsten</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Center for Neurological Rehabilitation, Zihlschlacht, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortner</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rheintal Werdenberg Sarganserland Hospital Group, Grabs, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruetti</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fuerstenland Toggenburg Hospital Group, Wil, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stocker</LastName><ForeName>Reto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hirslanden Clinic, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vuichard-Gysin</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Thurgau Hospital Group, Muensterlingen, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research and Development, Swiss National Centre for Infection Prevention (Swissnoso), Berne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besold</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Geriatric Clinic St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sinai Health System, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risch</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Labormedizinisches Zentrum Dr Risch Ostschweiz AG, Buchs, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Private Universit&#xe4;t im F&#xfc;rstentum Liechtenstein, Triesen, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Laboratory Medicine, University Institute of Clinical Chemistry, University of Bern, Inselspital, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedl</LastName><ForeName>Andr&#xe9;e</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital Baden, Baden, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlegel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vernazza</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuster</LastName><ForeName>Stefan P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohler</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0427-8934</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SURPRISE (SURveillance of infectious diseases among health PRofessionals In SwitzErland) Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2023 Sep 11;77(5):799. doi: 10.1093/cid/ciad292</RefSource><PMID Version="1">37160734</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">healthcare workers</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword><Keyword MajorTopicYN="N">viral variant</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. A. M. has received grant funding outside of the current work from Pfizer, SanofiPasteur, and Merck (paid to their institution); consulting fees from Sienna Senior Living (paid to the author); as well as honoraria for advisory boards, webinars, and/or Data and Safety Monitoring Board (DSMB) membership for AstraZeneca, Biogen, GlaxoSmithKline, Janssen, Medicago, Merck, Moderna, Novavax, Pfizer, and SanofiPasteur. A. M. also received travel support from Moderna. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Besold</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brucher</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cusini</LastName><ForeName>Alexia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Egger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedl</LastName><ForeName>Andr&#xe9;e</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goppel</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gr&#xe4;ssli</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kahlert</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keller</LastName><ForeName>Joelle</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kessler</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohler</LastName><ForeName>Philipp</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuster</LastName><ForeName>Stefan P</ForeName><Initials>SP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leal</LastName><ForeName>Onicio</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lemmenmeier</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGeer</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleeb</LastName><ForeName>Dorette Meier</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xf6;ller</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xf6;ller</LastName><ForeName>J Carsten</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Maja F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Musa</LastName><ForeName>Vaxhid</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortner</LastName><ForeName>Manuela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rieder</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Risch</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruetti</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlegel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmid</LastName><ForeName>Hans-Ruedi</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stocker</LastName><ForeName>Reto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vernazza</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Kietzell</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vuichard-Gysin</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiggli</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>2</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36905145</ArticleId><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad143</ArticleId><ArticleId IdType="pii">7076063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Phillips S, Williams MA. Confronting our next national health disaster&#x2014;long-haul Covid. N Engl J Med 2021; 385:577&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34192429</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open 2021; 4:e2111417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022; 226:1593&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators . Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022; 328: 1604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter RS, Nieters A, Kr&#xe4;usslich H-G, et al. . Post-acute sequelae of COVID-19 six to 12 months after infection: population based study. BMJ 2022; 379:e071050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9557001</ArticleId><ArticleId IdType="pubmed">36229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, et al. . Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study. Lancet 2022; 399:1303&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Strahm C, Seneghini M, G&#xfc;sewell S, et al. . Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection&#x2014;results of a prospective multicenter cohort. Clin Infect Dis 2022; 75:e1011&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383387</ArticleId><ArticleId IdType="pubmed">35090015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmer T, Borzikowsky C, Lieb W, et al. . Severity, predictors and clinical correlates of post-COVID syndrome (PCS) in Germany: a prospective, multi-centre, population-based cohort study. EClinicalMedicine 2022; 51:101549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9289961</ArticleId><ArticleId IdType="pubmed">35875815</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with Delta versus Omicron variants of SARS-CoV-2. Lancet 2022; 399:2263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, et al. . Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA 2022; 328:676&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022; 28:1461&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. . Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022; 22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. . Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open 2022; 5:e2238804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Vetter P, Chappuis F, Kaiser L, Guessous I; CoviCare Study Team . Prevalence of post-COVID condition 12 weeks after Omicron infection compared to negative controls and association with vaccination status. Clin Infect Dis 2023; 76:1567&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">36519381</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for characterizing long COVID. Nat Med 2021; 27:1129&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">34140704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert CR, Persi R, G&#xfc;sewell S, et al. . Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers&#x2014;a multicentre cross-sectional study. Clin Microbiol Infect 2021; 27:1336&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131187</ArticleId><ArticleId IdType="pubmed">34020033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler P, G&#xfc;sewell S, Seneghini M, et al. . Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19&#x2014;a prospective multicenter cohort study. BMC Med 2021; 19:270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8514323</ArticleId><ArticleId IdType="pubmed">34649585</ArticleId></ArticleIdList></Reference><Reference><Citation>Riester E, Findeisen P, Hegel JK, et al. . Performance evaluation of the Roche Elecsys anti-SARS-CoV-2 S immunoassay. J Virol Methods 2021; 297:114271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8393518</ArticleId><ArticleId IdType="pubmed">34461153</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagama Y, Komase Y, Kaku N, et al. . Detecting waning serological response with commercial immunoassays: 18-month longitudinal follow-up of anti-SARS-CoV-2 nucleocapsid antibodies. Microbiol Spectr 2022; 10:e00986-22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9430644</ArticleId><ArticleId IdType="pubmed">35867423</ArticleId></ArticleIdList></Reference><Reference><Citation>
Federal Office of Public Health . Virus variants overview. Available at: https://www.covid19.admin.ch/en/epidemiologic/virus-variants. Accessed 1 April 2021.</Citation></Reference><Reference><Citation>Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46:1121&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">2803071</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med 2001; 16:606&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1495268</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. J Health Soc Behav 1997; 38:21&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">9097506</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Boon GJAM, Barco S, et al. . The post-COVID-19 Functional Status Scale: a tool to measure functional status over time after COVID-19. Eur Respir J 2020; 56:2001494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado FVC, Meys R, Delbressine JM, et al. . Construct validity of the post-COVID-19 Functional Status Scale in adult subjects with COVID-19. Health Qual Life Outcomes 2021; 19:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7856622</ArticleId><ArticleId IdType="pubmed">33536042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med 2021; 27:626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazukhina E, Andreeva M, Spiridonova E, et al. . Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Med 2022; 20:244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9257572</ArticleId><ArticleId IdType="pubmed">35794549</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, et al. . Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis 2022; 74:1191&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad A, Janda A, Renk H, et al. . Long COVID symptoms in exposed and infected children, adolescents and their parents one year after SARS-CoV-2 infection: a prospective observational cohort study. EBioMedicine 2022; 84:104245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9495281</ArticleId><ArticleId IdType="pubmed">36155957</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjelltveit EB, Blomberg B, Kuwelker K, et al. . Symptom burden and immune dynamics 6 to 18 months following mild severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2): a case-control study. Clin Infect Dis 2023; 76:e60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384725</ArticleId><ArticleId IdType="pubmed">35959897</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmsdal G, Hanusson KD, Kristiansen MF, et al. . Long COVID in the long run&#x2014;23-month follow-up study of persistent symptoms. Open Forum Infect Dis 2022; 9:ofac270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9308378</ArticleId><ArticleId IdType="pubmed">35891696</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes Paranhos AC, Nazareth Dias &#xc1;R, Machado da Silva LC, et al. . Sociodemographic characteristics and comorbidities of patients with long COVID and persistent olfactory dysfunction. JAMA Netw Open 2022; 5:e2230637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9459661</ArticleId><ArticleId IdType="pubmed">36074464</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka S, Tsuzuki S, Suzuki M, et al. . Post COVID-19 condition of the omicron variant of SARS-CoV-2. J Infect Chemother 2022; 28:1546&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9365517</ArticleId><ArticleId IdType="pubmed">35963600</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus P, Gunnes N, Tveito K, et al. . Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine 2015; 33:6173&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26475444</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen I, Thomas JM, Hamilton WT, White PD. Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. QJM 2006; 99:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330509</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med 2022; 28:911&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Adriaenssens N, Scholtes B, Bruyndonckx R, et al. . Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up. BMJ Open 2022; 12:e065897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9485641</ArticleId><ArticleId IdType="pubmed">36123069</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 2021; 18:e1003773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson MM, Qasmieh SA, Kulkarni SG, et al. . The epidemiology of long COVID in US adults. Clin Infect Dis 2023; 76:1636&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">36542514</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>